Molecular Formula | C17H18Cl2N2O |
Molar Mass | 337.24362 |
Melting Point | ND |
Solubility | DMSO: ≥5mg/mL |
Appearance | powder |
Color | white to beige |
Storage Condition | -20°C |
In vitro study | Etifoxine (EFX), at concentrations ranging from 10 to 300 μM (higher concentrations limited its solubility), produces a dose-dependent increase in the [3H]muscimol binding at equilibrium, to 155±2% of its control value at 300 μM EFX. |
In vivo study | Etifoxine competitively inhibits [ 35 S]TBPS binding with micromolar potency in rat brain. Etifoxine (3.125-50 mg/kg) exhibits more pronounced anxiolytic and anticonvulsant effects in the BALB/cByJ mice compared to the C57BL/6J mice. Animal Model: Six-week old BALB/cByJ and C57BL/6J mice (20-25 g). Dosage: 3.125-50 mg/kg. Administration: Intraperitoneal inhection. Result: Significantly increased the amount of time spent on the open arms at the 12.5 mg/kg dose when compared to vehicle (p = 0.009) in BALB/cByJ mice but produced no effect in C57B/6J mice. BALB/cByJ mice compared with C57BL/6J mice exhibited significantly (p < 0.012) lower plasma levels of the compound at 15 and 30 min. |
Hazard Symbols | Xn - Harmful |
Risk Codes | 22 - Harmful if swallowed |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.965 ml | 14.826 ml | 29.652 ml |
5 mM | 0.593 ml | 2.965 ml | 5.93 ml |
10 mM | 0.297 ml | 1.483 ml | 2.965 ml |
5 mM | 0.059 ml | 0.297 ml | 0.593 ml |